Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Raises Questions About New-Technology Payment Candidates

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific’s Watchman stroke device, Medtronic and Bard’s drug-coated balloons, Cardiovascular Systems atherectomy systems and two other devices each come in for criticism in the Medicare agency’s consideration of the next round of inpatient bonus payments for new technologies.

You may also be interested in...



National Medicare Analysis Opened For Watchman Device

CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.

Boston Sci’s Watchman Stroke Device Finally Lands FDA Approval, With Favorable Labeling

Three separate FDA advisory panels examined the clinical data supporting the left-atrial appendage closure device and struggled to identify exactly which patients it benefits. But FDA has finally approved Watchman with an indication that analysts say will support meaningful market action for Boston Scientific. Reimbursement policies, however, remain a question mark.

Let The U.S. Drug-Coated Balloon Battle Begin

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT033828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel